These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38243167)
1. Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020-2021. Mashal MT; Eltayeb D; Higgins-Steele A; El Sheikh IS; Abid NS; Shukla H; Machado L; Jafari H BMC Public Health; 2024 Jan; 24(1):235. PubMed ID: 38243167 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733 [TBL] [Abstract][Full Text] [Related]
3. Acute flaccid paralysis surveillance performance from 2011 to 2020 in Jonglei State, South Sudan: progress and challenges encountered. Jil JM; Tegegne AA; Maleghemi S; Berta KK; Birru TG; Kilo OTD Pan Afr Med J; 2022; 42(Suppl 1):11. PubMed ID: 36158927 [TBL] [Abstract][Full Text] [Related]
4. A circulating vaccine-derived poliovirus type 2 outbreak in a chronic conflict setting: a descriptive epidemiological study in South Sudan - 2020 to 2021. Tegegne AA; Anyuon AN; Legge GA; Ferede MA; Isaac Z; Laku KA; Biadgilign S; Kilo OTD; Ndenzako F; Modjirom N; Olu OO; Maleghemi S BMC Infect Dis; 2023 Nov; 23(1):816. PubMed ID: 37990165 [TBL] [Abstract][Full Text] [Related]
5. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020. Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925 [TBL] [Abstract][Full Text] [Related]
6. Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic. Molodecky NA; Jafari H; Safdar RM; Ahmed JA; Mahamud A; Bandyopadhyay AS; Shukla H; Quddus A; Zaffran M; Sutter RW; Grassly NC; Blake IM Vaccine; 2023 Apr; 41 Suppl 1():A93-A104. PubMed ID: 34629206 [TBL] [Abstract][Full Text] [Related]
7. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021. Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733 [TBL] [Abstract][Full Text] [Related]
8. Stopping a polio outbreak in the midst of war: Lessons from Syria. Mbaeyi C; Moran T; Wadood Z; Ather F; Sykes E; Nikulin J; Al Safadi M; Stehling-Ariza T; Zomahoun L; Ismaili A; Abourshaid N; Asghar H; Korukluoglu G; Duizer E; Ehrhardt D; Burns CC; Sharaf M Vaccine; 2021 Jun; 39(28):3717-3723. PubMed ID: 34053791 [TBL] [Abstract][Full Text] [Related]
9. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018. Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908 [TBL] [Abstract][Full Text] [Related]
10. Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak. Kidanne L; Bisrat F; Mohammed M; Deyessa N Pan Afr Med J; 2022; 42():46. PubMed ID: 35949467 [TBL] [Abstract][Full Text] [Related]
11. Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020. Morais A; Morais J; Felix M; Neto Z; Madaleno V; Umar AS; Panda N; Lemma F; Chivale JAL; Cavalcante DG; Davlantes E; Ghiselli M; Espinosa C; Whiteman A; Iber J; Henderson E; Bullard K; Jorba J; Burns CC; Diop O; Gumede N; Seakamela L; Howard W; Frawley A Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A48-A57. PubMed ID: 36803869 [TBL] [Abstract][Full Text] [Related]
12. Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis. Al-Qassimi MA; Al Amad M; Al-Dar A; Al Sakaf E; Al Hadad A; Raja'a YA BMC Infect Dis; 2024 Mar; 24(1):321. PubMed ID: 38491425 [TBL] [Abstract][Full Text] [Related]
13. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020. Macklin GR; Goel AK; Mach O; Tallis G; Ahmed JA; O'Reilly KM; Grassly NC; Diop OM Vaccine; 2023 Apr; 41 Suppl 1():A19-A24. PubMed ID: 36008232 [TBL] [Abstract][Full Text] [Related]